Anti-ACHD/ CHRND/ ACHRD monoclonal antibody
Anti-ACHD/ CHRND/ ACHRD antibody for FACS & in-vivo assay
Go to CHRND/CHRND products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0263-Ab-1/ GM-Tg-hg-MP0263-Ab-2 | Anti-Human CHRND monoclonal antibody | Human |
GM-Tg-rg-MP0263-Ab-1/ GM-Tg-rg-MP0263-Ab-2 | Anti-Rat CHRND monoclonal antibody | Rat |
GM-Tg-mg-MP0263-Ab-1/ GM-Tg-mg-MP0263-Ab-2 | Anti-Mouse CHRND monoclonal antibody | Mouse |
GM-Tg-cynog-MP0263-Ab-1/ GM-Tg-cynog-MP0263-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CHRND monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0263-Ab-1/ GM-Tg-felg-MP0263-Ab-2 | Anti-Feline CHRND monoclonal antibody | Feline |
GM-Tg-cang-MP0263-Ab-1/ GM-Tg-cang-MP0263-Ab-2 | Anti-Canine CHRND monoclonal antibody | Canine |
GM-Tg-bovg-MP0263-Ab-1/ GM-Tg-bovg-MP0263-Ab-2 | Anti-Bovine CHRND monoclonal antibody | Bovine |
GM-Tg-equg-MP0263-Ab-1/ GM-Tg-equg-MP0263-Ab-2 | Anti-Equine CHRND monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0263-Ab-1/ GM-Tg-hg-MP0263-Ab-2; GM-Tg-rg-MP0263-Ab-1/ GM-Tg-rg-MP0263-Ab-2; GM-Tg-mg-MP0263-Ab-1/ GM-Tg-mg-MP0263-Ab-2; GM-Tg-cynog-MP0263-Ab-1/ GM-Tg-cynog-MP0263-Ab-2; GM-Tg-felg-MP0263-Ab-1/ GM-Tg-felg-MP0263-Ab-2; GM-Tg-cang-MP0263-Ab-1/ GM-Tg-cang-MP0263-Ab-2; GM-Tg-bovg-MP0263-Ab-1/ GM-Tg-bovg-MP0263-Ab-2; GM-Tg-equg-MP0263-Ab-1/ GM-Tg-equg-MP0263-Ab-2 |
Products Name | Anti-CHRND monoclonal antibody |
Format | mab |
Target Name | CHRND |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CHRND benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ACHD/ CHRND/ ACHRD VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP0263 |
Target Name | CHRND |
Gene ID | 1144,11447,54240,713354,486162,101098322,281687,100064682 |
Gene Symbol and Synonyms | Achr-4,ACHRD,Acrd,CHRND,CMS2A,CMS3A,CMS3B,CMS3C,FCCMS,SCCMS |
Uniprot Accession | Q07001,P25110,P04759 |
Uniprot Entry Name | ACHD_HUMAN,ACHD_RAT,ACHD_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000135902 |
Target Classification | N/A |
The target: CHRND, gene name: CHRND, also named as ACHRD, CMS2A, CMS3A, CMS3B, CMS3C, FCCMS, SCCMS. The acetylcholine receptor of muscle has 5 subunits of 4 different types: 2 alpha and 1 each of beta, gamma and delta subunits. After acetylcholine binding, the receptor undergoes an extensive conformation change that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in this gene are a cause of multiple pterygium syndrome lethal type (MUPSL), congenital myasthenic syndrome slow-channel type (SCCMS), and congenital myasthenic syndrome fast-channel type (FCCMS). Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2015].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.